We are a Swiss pharmaceutical group providing solutions in more than 70 countries around the world.
Our group is mainly focused on therapeutic areas such as ophthalmology, rheumatology and neurology. Clinical research and privileged exchanges with both healthcare professionals and patients are always at the heart of our product development. TRB’s particular expertise lies above all in the production, packaging and therapeutic options relating to hyaluronic acid. These skills are evident throughout our wide range of products and related patents. Our Swiss affiliate, TRB CHEMEDICA SA, is based in Vouvry, in Valais. On this site, two manufacturing units and a research & development department work closely together. It’s also where the whole range of OSTENIL® products are manufactured.
TRB CHEMEDICA SA’s Swiss portfolio includes ophthalmological products as VISMED® – hyaluronic acid based eye drops. Thanks to their unique composition, this product has set a new benchmark and become the treatment of choice for dry eyes. In orthopaedics, TRB CHEMEDICA SA has set new standards with OSTENIL® product range – intraarticular injections to treat post-traumatic and degenerative joint disease, such as osteoarthritis. In Switzerland, Ostenil was the first product line based on biofermentative hyaluronic acid to be authorised for intra-articular use in all synovial joints. For 20 years, the OSTENIL® brand has been recognised for its efficacy and tolerability.
Key facts about the company
Number of employees (worldwide)